Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 678

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 2
Chunk 678
---
 have historically been the cost associated with our initial investment in pre-clinical research and development activities.
We expect research and development expenses to increase in the future as we advance Telomir-1 into and through clinical trials and
pursue regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support, and contract
manufacturing. In addition, we will evaluate opportunities to acquire or in-license additional product candidates and technologies, which
may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development
costs.

The
process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely
development and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be
affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we
are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue
from the commercialization and sale of our product candidates.

General
and Administrative Expenses

General
and administrative expenses consist of administrative functions, as well as fees paid for legal consulting fees and facilities costs
not otherwise included in research and development expenses. Legal costs include general corporate legal fees and license costs. We expect
to incur additional expenses as a result of becoming a public company, including expenses related to compliance with the rules and regulations
of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.

48

Results
of Operations for years ended December 31, 2024 and 2023

    Year
    Ended December 31, 

    2024  
    2023 
  
    Revenues 
    $
    -  
    $
    - 

    Operating costs: 

    General and
    administrative expenses 
     9,636,333  
     600,192 
  
    Related party travel costs 
     370,500  
     1,767,550 
  
    Research
    and development expenses 
     2,235,341  
     1,574,306 
  
    Total
    operating costs 
     12,242,174  
     3,942,048 

    Interest
    income 
     48,000  
     - 
  
    Interest expense 
     (4,338,